The vicious circle of heart failure: how the body's defense becomes its enemy
In short: When the heart fails to pump effectively, the body triggers a series of emergency responses. While these mechanisms are designed to compensate for injury, they often create a self-perpetuating cycle of deterioration. Understanding this transition from adaptation to pathology is key to modern cardiac treatment.
Heart failure is a global epidemic affecting approximately 1% to 2% of the world's population. It is defined as a clinical syndrome where structural or functional cardiac abnormalities lead to reduced cardiac output or elevated intracardiac pressures. While the symptoms—such as fatigue, dyspnoea, and ankle swelling—are distinct, the underlying causes and phenotypes can vary significantly between individuals. The European Society of Cardiology defined these clinical parameters in 2016. These conditions can manifest during rest or physical stress. Patients may also exhibit signs like pulmonary crackles or elevated jugular venous pressure.
The progression of the disease is driven by cellular, structural, and neurohumoral modulations following a cardiac injury, such as a myocardial infarction or changes in preload and afterload. In response, the body activates the sympathoadrenergic and renin-angiotensin-aldosterone systems. These are intended to be adaptive, but they ultimately lead to a 'vicious circle' characterized by volume overload, tachycardia, and further decline in cellular function. This cycle can be measured by increased levels of neurohormones like norepinephrine and natriuretic peptides such as NT-pro BNP. These cellular changes influence both intra- and intercellular behaviors. The resulting deterioration of function can occur in an acute or chronic manner. These neurohumoral modulations are triggered by specific injuries like increased afterload.
Clinical management focuses on breaking this cycle. Because the pathophysiology differs between heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), treatment must be individualized. Current strategies involve modulating these overactive systems using medications like beta-blockers, ACE-inhibitors, and ARNI to improve symptoms and outcomes. Because there is no single heart failure-specific clinical sign, diagnosis relies on a mix of noninvasive tools like echocardiography and NMR, alongside invasive procedures like heart catheterization. Beyond pharmacological interventions, surgical and interventional therapies remain available options. Doctors also emphasize the prevention of cardiovascular risk factors to lower overall risk. Precise understanding of the underlying pathophysiology is required to select the correct individual therapy.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Heart failure with reduced and preserved ejection fraction, pathophysiology and treatment
- Also: Pathophysiology of heart failure
To cite this card, link to https://intellectplus.co.uk/app/science-heart-failure-with-reduced-and-preserved-ejection-fraction-p.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Science · Latest · A–Z · All topics
